Find, compare & contact
Bromothalonil
API Manufacturers & Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Bromothalonil API 35691-65-7?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Bromothalonil. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Bromothalonil
- Synonyms:
- 1,2-Dibromo-2,4-dicyanobutane , 2-Bromo-2-(bromomethyl) glutaronitrile , 2-Bromo-2-(bromomethyl) pentanedinitrile , BBMG , Glutaronitrile, 2-bromo-2-(bromomethyl)- , MDBGN , Methyldibromo Glutaronitrile , Methyldibromoglutaronitrile
- Cas Number:
- 35691-65-7
- DrugBank number:
- DB14199
- Unique Ingredient Identifier:
- YX089CPS05
General Description:
Bromothalonil, identified by CAS number 35691-65-7, is a notable compound with significant therapeutic applications. Bromothalonil, also known as Methyldibromo glutaronitrile (MDBGN), is a widely used preservative that can be found in many personal hygiene and industrial products. It is also a known allergen and dermatological irritant that has been banned in many EU countries due to increasing rates of contact allergy . In 2005, MDBGN was named in the top 15 most frequently positive allergens identified in patch tests by the North American Contact Dermatitis Group (NACDG). Sensitivity to Bromothalonil may be identified with a clinical patch test.
Indications:
This drug is primarily indicated for: Bromothalonil is approved for use within allergenic epicutaneous patch tests which are indicated for use as an aid in the diagnosis of allergic contact dermatitis (ACD) in persons 6 years of age and older. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.
Categories:
Bromothalonil is categorized under the following therapeutic classes: Allergens, Antigens, Biological Factors, Cell-mediated Immunity, Compounds used in a research, industrial, or household setting, Increased Histamine Release, Pharmaceutic Aids, Pharmaceutical Preparations, Preservatives, Pharmaceutical, Standardized Chemical Allergen. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Bromothalonil is a type of Anti-allergy agents
Anti-allergy agents, also known as antihistamines, are a crucial category of pharmaceutical active pharmaceutical ingredients (APIs) used in the treatment of allergies. These substances work by blocking the effects of histamine, a chemical released by the body's immune system during an allergic reaction.
Antihistamines act on histamine receptors, preventing them from binding to target cells and thus inhibiting the release of allergic symptoms such as itching, sneezing, and watery eyes. These APIs can be classified into two generations based on their characteristics.
First-generation antihistamines, such as diphenhydramine and chlorpheniramine, are known for their sedative properties due to their ability to cross the blood-brain barrier. Although effective in relieving allergy symptoms, they often cause drowsiness, impairing daily activities.
Second-generation antihistamines, including cetirizine and loratadine, were developed to address the sedative side effects of their predecessors. These newer APIs have a higher selectivity for peripheral histamine receptors and a reduced ability to penetrate the central nervous system, resulting in reduced sedation.
Anti-allergy APIs are available in various formulations, including oral tablets, liquids, nasal sprays, and eye drops. They are widely used to alleviate allergic reactions caused by pollen, dust mites, pet dander, and other environmental allergens. These agents provide relief from symptoms such as itching, runny nose, congestion, and hives.
In summary, anti-allergy agents are a vital category of APIs used to manage allergic reactions. They block the effects of histamine, providing relief from allergy symptoms. The development of second-generation antihistamines has significantly reduced sedative side effects, improving patient comfort. These APIs are available in different formulations, catering to the diverse needs of allergy sufferers.
